Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.33 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | KAT6A | Q92794 | 4/20 | 0.33 |
| ▸ | KAT5 | Q92993 | 4/20 | 0.33 |
| ▸ | KAT8 | Q9H7Z6 | 3/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.32 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.32 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL977199 | 0.91 | KDM4E (0.36) | SCN9AKCNA5SCN7ASCN5AKAT6A | |
| SCHEMBL975708 | 0.86 | SCN9A (0.38) | SCN9ASCN7ASCN5AKAT6AKAT5 | |
| SCHEMBL975169 | 0.84 | MEN1 (0.39) | SCN9ASCN7ASCN5ASLC6A9 | |
| SCHEMBL974851 | 0.83 | SLC6A9 (0.38) | SCN9ASCN7ASCN5AKAT6AKAT5 | |
| SCHEMBL977764 | 0.83 | CCR2 (0.40) | SCN9ACCR2UTS2R | |
| SCHEMBL977431 | 0.82 | SCN9A (0.38) | SCN9ACCR2KAT6AKAT5KAT8 | |
| SCHEMBL976397 | 0.80 | SLC6A9 (0.34) | CCR2SLC6A9 | |
| SCHEMBL977066 | 0.80 | ENPP2 (0.34) | SCN9ACCR2P2RX7SLC6A9UTS2R | |
| SCHEMBL974361 | 0.79 | EPHX2 (0.34) | CCR2SLC6A9UTS2R | |
| SCHEMBL978464 | 0.78 | KMT2A (0.37) | SCN9ACCR2SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445478-B2 | Azetidine derivatives, their preparation and their application in therapy | SANOFI (FR) | 2013-05-21 | — | — | US | claimed |
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | QDPR, AZI2, ADRA1B | SCN9A 694/4885CCR2 1287/4885KCNA5 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.